Ayunova Pharmaceutical LLP

Filgrastim (G-CSF) Pre-Filled Syringe (PFS) 480 mcg / 0.8 ml

Filgrastim (Granulocyte Colony-Stimulating Factor, G-CSF) PFS is a sterile, ready-to-use injectable formulation that stimulates the production of neutrophils in the bone marrow. It is primarily used to prevent and treat neutropenia in patients undergoing chemotherapy, bone marrow transplantation, or other conditions causing low white blood cell counts. The pre-filled syringe ensures accurate dosing and convenient administration, improving patient compliance and safety.

• Filgrastim (Recombinant G-CSF): 480 mcg

• Excipients: Water for injection, stabilizers, buffer agents, and BP/USP-grade excipients

Each pre-filled syringe delivers 480 mcg in 0.8 ml.

• Prevention and treatment of neutropenia caused by chemotherapy

• Support for patients undergoing bone marrow or stem cell transplantation

• Treatment of congenital, cyclic, or idiopathic neutropenia

• Mobilization of hematopoietic stem cells for transplantation

• Reduces risk of infections in immunocompromised patients

• Administered subcutaneously or intravenously as per physician guidance

• Dose depends on patient weight, condition, and type of therapy

• Must be used under supervision of a qualified healthcare professional

• Pre-filled syringe for precise and convenient dosing

• Sterile and BP/USP-compliant formulation

• Recombinant G-CSF for effective neutrophil stimulation

• Supports infection prevention in immunocompromised patients

• Suitable for hospital, clinical, and homecare use under supervision

• 0.8 ml PFS containing 480 mcg Filgrastim

• Available in blister packs or cartons

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light and moisture

• Keep out of reach of children

Pegfilgrastim Pre-Filled Syringe (PFS) 6 mg / 0.6 ml

Pegfilgrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) used to reduce the incidence of neutropenia and related infections in patients receiving myelosuppressive chemotherapy. It is a pegylated form of filgrastim, which provides prolonged activity and allows once-per-chemotherapy-cycle dosing. The pre-filled syringe ensures accurate dosing, convenience, and safe administration.

• Pegfilgrastim: 6 mg

• Excipients: Water for injection, buffers, stabilizers, and BP/USP-grade excipients

Each PFS delivers a precise dose of 6 mg in 0.6 ml.

• Prevention of chemotherapy-induced neutropenia

• Reduction of risk of febrile neutropenia

• Supportive care in cancer patients undergoing cytotoxic chemotherapy

• Reduction of infection risk due to low neutrophil count

• Administered via subcutaneous injection

• Typically given once per chemotherapy cycle, as prescribed by a physician

• Must be used under supervision of a qualified healthcare professional

• Long-acting G-CSF requiring fewer injections

• Pre-filled syringe for accurate, ready-to-use dosing

• Sterile, pyrogen-free, and BP/USP-compliant formulation

• Improves patient convenience and compliance

• 0.6 ml PFS containing 6 mg Pegfilgrastim

• Supplied in individual blister packs or cartons

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light

• Keep out of reach of children

Bevacizumab Ophthalmic Pre-Filled Syringe (PFS) 1.25 mg / 0.05 ml

Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby preventing abnormal blood vessel growth and vascular leakage in the eye. Although primarily approved for oncology use, ophthalmic formulations are widely used off-label for treating retinal vascular disorders such as neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). The pre-filled syringe (PFS) ensures accurate dosing, sterile administration, and improved patient safety.

• Bevacizumab: 1.25 mg

• Excipients: Buffer, stabilizers, and BP/USP-grade excipients

Each pre-filled syringe delivers 1.25 mg in 0.05 ml for intravitreal injection.

• Neovascular (wet) age-related macular degeneration (AMD)

• Diabetic macular edema (DME)

• Macular edema following retinal vein occlusion (RVO)

• Myopic choroidal neovascularization (mCNV)

• Other VEGF-mediated retinal disorders (off-label ophthalmic use)

• Administered via intravitreal injection by a qualified ophthalmologist

• Typical dosage: 1.25 mg once every 4–6 weeks; may vary based on patient condition and response

• Strict aseptic technique required during administration

• VEGF-A inhibitor for effective control of retinal neovascularization and edema

• Pre-filled syringe for precise, ready-to-use intravitreal dosing

• Sterile, pyrogen-free, and BP/USP-compliant formulation

• Supports vision preservation and slows progression of retinal diseases

• 0.05 ml PFS containing 1.25 mg Bevacizumab

• Supplied in sterile individual packs suitable for ophthalmic use

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light

• Keep out of reach of children

Palivizumab Pre-Filled Syringe (PFS) 50 mg / 0.5 ml

Palivizumab is a humanized monoclonal antibody used for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in high-risk infants and young children. It binds to the RSV fusion (F) protein, inhibiting viral entry into host cells. The pre-filled syringe (PFS) ensures accurate dosing, sterility, and convenient administration, making it suitable for hospital and clinical use.

• Palivizumab: 50 mg

• Excipients: Buffer solution, stabilizers, and BP/USP-grade excipients

Each pre-filled syringe delivers 50 mg in 0.5 ml for intramuscular injection.

• Prevention of serious lower respiratory tract infection caused by RSV in:

  • Premature infants (≤35 weeks gestational age)

  • Infants with bronchopulmonary dysplasia

  • Children with hemodynamically significant congenital heart disease

• Seasonal prophylaxis during RSV outbreaks

• Administered via intramuscular injection

• Standard dose: 15 mg/kg body weight, given once a month during the RSV season

• Must be administered under the supervision of a qualified healthcare professional

• Monoclonal antibody for RSV prophylaxis in high-risk infants

• Pre-filled syringe for accurate and convenient dosing

• Sterile, pyrogen-free, and BP/USP-compliant formulation

• Reduces hospitalization due to RSV infections

• 0.5 ml PFS containing 50 mg Palivizumab

• Supplied in individual blister packs or cartons

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light

• Keep out of reach of children

Methotrexate Pre-Filled Syringe (PFS) 25 mg / 0.4–1 ml

Methotrexate is an antimetabolite and antifolate drug used in the treatment of various conditions, including rheumatoid arthritis (RA) and certain malignancies. It inhibits dihydrofolate reductase, interfering with DNA synthesis, repair, and cellular replication. The pre-filled syringe (PFS) formulation provides accurate dosing, sterility, and ease of administration for both hospital and clinical use.

• Methotrexate: 25 mg

• Excipients: Water for injection, stabilizers, and BP/USP-grade excipients

Each pre-filled syringe delivers 25 mg of Methotrexate in 0.4–1 ml depending on manufacturer specification.

• Rheumatoid Arthritis (RA): Management of moderate to severe active RA

• Psoriasis: Severe cases requiring systemic therapy

• Oncology: Treatment of leukemia, lymphoma, osteosarcoma, and other malignancies

• Other Autoimmune Disorders: As prescribed by a physician

• Administered via subcutaneous or intramuscular injection as per physician guidance

• Dosage depends on patient condition, body surface area, and indication

• Must be administered under close supervision due to potential toxicity

• Accurate, ready-to-use pre-filled syringe for patient convenience

• Sterile and BP/USP-compliant formulation

• Supports systemic therapy in autoimmune diseases and oncology

• Reduces risk of dosing errors and contamination

• 0.4–1 ml PFS containing 25 mg Methotrexate

• Supplied in individual blister packs or cartons

• Store at 2–8°C (refrigerated)

• Protect from light

• Do not freeze

• Keep out of reach of children

Imatinib Mesylate Tablets BP – 400 mg

Imatinib Mesylate 400 mg Tablets BP is a targeted anticancer (tyrosine kinase inhibitor) medication used in the treatment of specific cancers caused by abnormal protein tyrosine kinases.

Imatinib works by selectively inhibiting BCR-ABL tyrosine kinase, as well as c-KIT and PDGFR, thereby blocking cancer cell growth and inducing apoptosis. It is widely used as a first-line therapy in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).

This formulation offers high efficacy, oral convenience, and improved survival outcomes, making it an essential medicine in oncology treatment protocols.

Each film-coated tablet contains:

• Imatinib Mesylate BP – equivalent to Imatinib 400 mg

• Excipients: q.s. (suitable tablet base)

Imatinib Mesylate Tablets are indicated for:

1. Chronic Myeloid Leukemia (CML)

   • Philadelphia chromosome-positive (Ph+) CML in chronic, accelerated, or blast crisis phase

2. Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)

1. Gastrointestinal Stromal Tumors (GIST)

   • Unresectable or metastatic GIST

   • Adjuvant treatment after surgical resection

1. Myelodysplastic / Myeloproliferative Diseases (MDS/MPD) associated with PDGFR rearrangements

2. Hypereosinophilic Syndrome (HES) / Chronic Eosinophilic Leukemia (CEL)

3. Dermatofibrosarcoma Protuberans (DFSP) – unresectable or recurrent cases

• Usual adult dose: 400 mg once daily or as prescribed by oncologist

• To be taken orally with food and a full glass of water

• Dose adjustments based on clinical response and tolerance

• Long-term therapy under medical supervision

• Blister packs: 10 tablets per strip

• Available in bulk packaging for institutional supply

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Dasatinib Tablets BP – 100 mg

Dasatinib 100 mg Tablets BP is a second-generation tyrosine kinase inhibitor (TKI) used in the treatment of Philadelphia chromosome-positive (Ph+) leukemias.

Dasatinib works by potently inhibiting BCR-ABL kinase, along with SRC family kinases, resulting in effective suppression of cancer cell proliferation and induction of apoptosis. It is especially useful in patients resistant or intolerant to imatinib therapy.

This oral formulation offers rapid action, high potency, and convenient once-daily dosing, making it an essential medicine in modern leukemia management.

Each film-coated tablet contains:

• Dasatinib BP – 100 mg

• Excipients: q.s. (suitable tablet base)

Dasatinib Tablets are indicated for:

1. Chronic Myeloid Leukemia (CML)

   • Philadelphia chromosome-positive (Ph+) CML in chronic, accelerated, or blast phase

   • Patients resistant or intolerant to prior therapy, including imatinib

2. Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)

   • Adult patients with disease resistant or intolerant to previous treatments

1. Second-line or subsequent therapy for CML and Ph+ ALL

2. Rapid cytogenetic and molecular response in advanced disease stages

• Typical adult dose: 100 mg orally once daily or as prescribed by an oncologist

• Can be taken with or without food

• Tablets should be swallowed whole; do not crush or chew

• Dose modification based on hematologic and non-hematologic toxicities

• Blister packs: 10 tablets per strip

• Bulk packaging available for institutional and hospital supply

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Nilotinib Tablets BP – 200 mg

Nilotinib 200 mg Tablets BP is a second-generation tyrosine kinase inhibitor (TKI) used for the treatment of Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML).

Nilotinib is designed to selectively and potently inhibit BCR-ABL tyrosine kinase, including many imatinib-resistant mutations, thereby blocking abnormal cancer cell signaling and proliferation. It provides rapid, deep molecular responses and is widely used as first-line or second-line therapy in CML patients.

Each hard gelatin capsule/tablet contains:

• Nilotinib BP – 200 mg

• Excipients: q.s. (pharmaceutical grade)

Nilotinib Tablets are indicated for:

1. Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML)

   • Newly diagnosed chronic phase CML

   • CML patients resistant or intolerant to prior therapy, including imatinib

1. Chronic and accelerated phase CML

2. Second-line therapy where first-generation TKIs are ineffective

3. Achieving rapid molecular and cytogenetic response

• Usual adult dose: 400 mg twice daily (2 × 200 mg) or as prescribed

• Must be taken on an empty stomach

  • No food 2 hours before and 1 hour after dosing

• Swallow whole with water; do not crush or chew

• Therapy to be continued under oncologist supervision

• Blister packs: 10 capsules/tablets per strip

• Institutional and bulk packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Bosutinib Tablets BP – 400 mg

Bosutinib 400 mg Tablets BP is a second-generation tyrosine kinase inhibitor (TKI) indicated for the treatment of Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML).

Bosutinib selectively inhibits BCR-ABL and Src family kinases, leading to effective suppression of leukemic cell proliferation while minimizing activity against other kinases. It is commonly used in patients who are resistant or intolerant to prior tyrosine kinase inhibitor therapy such as imatinib, dasatinib, or nilotinib.

Each film-coated tablet contains:

• Bosutinib BP – 400 mg

• Excipients: q.s. (pharmaceutical grade)

Bosutinib Tablets are indicated for:

1. Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML)

   • Chronic phase, accelerated phase, or blast phase

2. Patients resistant or intolerant to prior TKI therapy

   • Including imatinib, dasatinib, or nilotinib

1. Second-line or subsequent therapy in CML

2. Long-term disease control with targeted kinase inhibition

• Typical adult dose: 400 mg orally once daily

• Must be taken with food to improve absorption

• Tablets should be swallowed whole with water

• Dose modifications based on tolerability and hepatic function

• Blister packs: 10 tablets per strip

• Bulk / institutional packaging available

• Store below 25°C

• Protect from light and moisture

Thalidomide Tablets BP – 100 mg

Thalidomide 100 mg Tablets BP is an immunomodulatory and anticancer agent widely used in the treatment of multiple myeloma and selected inflammatory conditions.

Thalidomide exhibits anti-angiogenic, immunomodulatory, and anti-inflammatory properties, helping to inhibit tumor growth, suppress cytokine production, and enhance immune response. Due to its potency, thalidomide is used under strict medical supervision.

Each tablet contains:

• Thalidomide BP – 100 mg

• Excipients: q.s. (pharmaceutical grade)

Thalidomide Tablets are indicated for:

1. Multiple Myeloma

   • In combination with dexamethasone or other agents

2. Relapsed or refractory plasma cell disorders

1. Erythema Nodosum Leprosum (ENL)

   • Severe inflammatory complication of leprosy

2. Immunomodulatory therapy in selected chronic inflammatory conditions (as prescribed)

• Typical dose: 100 mg once daily, usually taken at bedtime

• Dose may be adjusted based on response and tolerance

• Tablets should be swallowed whole with water

• Use only under specialist supervision

• Blister packs: 10 tablets per strip

• Institutional and bulk packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Pazopanib Tablets BP – 200 mg

Pazopanib 200 mg Tablets BP is an oral anticancer medicine belonging to the class of multitargeted tyrosine kinase inhibitors (TKIs), primarily used for the treatment of advanced renal cell carcinoma and soft tissue sarcoma.

Pazopanib works by inhibiting multiple receptor tyrosine kinases, including VEGFR, PDGFR, and c-KIT, thereby blocking tumor angiogenesis and tumor cell proliferation. Its targeted mechanism helps slow disease progression while allowing convenient oral administration.

Each film-coated tablet contains:

• Pazopanib BP – 200 mg

• Excipients: q.s. (pharmaceutical grade)

Pazopanib Tablets are indicated for:

1. Advanced Renal Cell Carcinoma (RCC)

2. Advanced Soft Tissue Sarcoma (STS)

   • In patients who have received prior chemotherapy

1. Inhibition of tumor angiogenesis

2. Management of metastatic or unresectable tumors

• Usual adult dose: 800 mg once daily (as 4 × 200 mg tablets) or as prescribed

• Must be taken on an empty stomach

  • At least 1 hour before or 2 hours after food

• Tablets should be swallowed whole with water

• Dose modifications may be required based on hepatic function and tolerability

• Blister packs: 10 tablets per strip

• Institutional / bulk packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Sunitinib Tablets BP – 50 mg

Sunitinib 50 mg Tablets BP is an oral multitargeted tyrosine kinase inhibitor (TKI) used for the treatment of advanced renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (pNET).

Sunitinib works by inhibiting multiple receptor tyrosine kinases, including VEGFR, PDGFR, c-KIT, and FLT3, which are involved in tumor angiogenesis and cell proliferation. This targeted mechanism allows for effective management of metastatic or unresectable cancers while providing convenient oral dosing.

Each film-coated tablet contains:

• Sunitinib BP – 50 mg

• Excipients: q.s. (pharmaceutical grade)

Sunitinib Tablets are indicated for:

1. Advanced Renal Cell Carcinoma (RCC)

2. Gastrointestinal Stromal Tumors (GIST)

   • For patients resistant or intolerant to imatinib therapy

3. Pancreatic Neuroendocrine Tumors (pNET)

1. Inhibition of tumor angiogenesis

2. Management of metastatic or unresectable tumors

• Standard adult dose: 50 mg orally once daily for 4 weeks, followed by 2 weeks off (6-week cycle) or as prescribed

• Tablets should be taken on an empty stomach

• Swallow whole with water; do not crush or chew

• Dose adjustments may be required in hepatic impairment or adverse reactions

• Blister packs: 10 tablets per strip

• Bulk / institutional packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Sorafenib Tablets BP – 200 mg

Sorafenib 200 mg Tablets BP is an oral multikinase inhibitor used for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid carcinoma (DTC).

Sorafenib works by inhibiting multiple receptor tyrosine kinases, including VEGFR, PDGFR, RAF kinases, which play a key role in tumor cell proliferation, angiogenesis, and tumor progression. This targeted mechanism allows effective disease management in metastatic or unresectable cancers while providing convenient oral therapy.

Each film-coated tablet contains:

• Sorafenib BP – 200 mg

• Excipients: q.s. (pharmaceutical grade)

Sorafenib Tablets are indicated for:

1. Advanced Renal Cell Carcinoma (RCC)

2. Hepatocellular Carcinoma (HCC)

3. Differentiated Thyroid Carcinoma (DTC)

   • Refractory to radioactive iodine therapy

1. Inhibition of tumor angiogenesis and proliferation

2. Management of metastatic or unresectable tumors

• Standard adult dose: 400 mg (2 × 200 mg tablets) twice daily or as prescribed

• Tablets should be taken on an empty stomach

• Swallow whole with water; do not crush or chew

• Dose modifications may be required based on hepatic function, adverse effects, or tolerability

• Blister packs: 10 tablets per strip

• Institutional / bulk packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Lapatinib Tablets BP – 250 mg

Lapatinib 250 mg Tablets BP is an oral targeted anticancer medicine used primarily in the treatment of HER2-positive breast cancer.

Lapatinib works as a dual tyrosine kinase inhibitor, targeting HER2 (ErbB2) and EGFR (ErbB1) receptors, thereby blocking tumor cell proliferation and survival signaling pathways. It is often used in combination with other chemotherapeutic agents to improve treatment outcomes in advanced or metastatic breast cancer.

Each film-coated tablet contains:

• Lapatinib BP – 250 mg

• Excipients: q.s. (pharmaceutical grade)

Lapatinib Tablets are indicated for:

1. HER2-positive advanced or metastatic breast cancer

   • In combination with capecitabine for patients previously treated with anthracycline, taxane, and trastuzumab

2. HER2-positive breast cancer in combination with letrozole

   • For postmenopausal women with advanced disease

1. Inhibition of tumor cell proliferation and survival

2. Treatment of metastatic or progressive breast cancer after standard therapy

• Typical adult dose: 1,250 mg once daily (5 × 250 mg tablets) in combination with capecitabine or as prescribed

• Should be taken on an empty stomach at least 1 hour before or 1 hour after food

• Tablets should be swallowed whole with water

• Therapy must be monitored under oncologist supervision

• Blister packs: 10 tablets per strip

• Bulk / institutional packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Everolimus Tablets BP – 10 mg

Everolimus 10 mg Tablets BP is an oral mTOR (mammalian target of rapamycin) inhibitor used for the treatment of various cancers and transplant-related conditions.

Everolimus works by inhibiting the mTOR pathway, which is critical for cell growth, proliferation, angiogenesis, and survival. This targeted mechanism helps in slowing tumor progression and controlling abnormal cell growth, making it highly effective in advanced cancers and organ transplant therapy.

Each film-coated tablet contains:

• Everolimus BP – 10 mg

• Excipients: q.s. (pharmaceutical grade)

Everolimus Tablets are indicated for:

1. Advanced Renal Cell Carcinoma (RCC)

2. Subependymal Giant Cell Astrocytoma (SEGA) associated with tuberous sclerosis

3. Pancreatic Neuroendocrine Tumors (pNET)

1. Prevention of organ transplant rejection (renal, cardiac, or hepatic)

2. Inhibition of abnormal cell proliferation in other mTOR-driven conditions

1. Slowing tumor progression

2. Regulation of angiogenesis and immune response

• Typical adult dose: 10 mg once daily, or as prescribed

• Tablets should be taken at the same time every day with or without food

• Swallow whole with water; do not crush or chew

• Dose modifications may be required based on renal/hepatic function and adverse effects

• Therapy should be administered under oncologist or transplant specialist supervision

• Blister packs: 10 tablets per strip

• Institutional / bulk packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Doxorubicin Hydrochloride (HCl) for Injection BP

Doxorubicin HCl for Injection BP is a chemotherapeutic antineoplastic agent belonging to the anthracycline class. It is widely used in the treatment of various cancers, including leukemias, lymphomas, breast cancer, ovarian cancer, sarcomas, and other solid tumors.

Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, which prevents DNA replication and RNA synthesis, leading to apoptosis of rapidly dividing cancer cells.

Each vial contains:

• Doxorubicin Hydrochloride BP – 10 mg / 20 mg / 50 mg / 100 mg

• Excipients: q.s. for injection (sterile solution for IV use)

Ready for intravenous (IV) administration after reconstitution or dilution as per protocol.

Doxorubicin HCl for Injection is indicated for:

1. Hematological malignancies:

   • Acute lymphoblastic leukemia (ALL)

   • Acute myeloid leukemia (AML)

   • Hodgkin’s and non-Hodgkin’s lymphoma

2. Solid tumors:

   • Breast cancer

   • Ovarian cancer

   • Lung cancer

   • Sarcomas

3. Combination chemotherapy protocols for various cancers

4. Palliative therapy in advanced malignancies

• Adults: 60–75 mg/m² IV every 21 days (dose varies per protocol)

• Children: Dose calculated based on body surface area (mg/m²)

• Route: Slow IV injection or infusion over several minutes to hours

• Monitoring: Cardiac function, hematological parameters, and liver function should be monitored

• Precaution: Should be administered under experienced oncology supervision due to potential cardiotoxicity

• Vials: 10 mg / 20 mg / 50 mg / 100 mg per vial

• Sterile solution for IV use

• Bulk and institutional packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

• Avoid freezing

Epirubicin Hydrochloride (HCl) for Injection BP

Epirubicin HCl for Injection BP is a potent anthracycline antineoplastic (chemotherapy) agent used in the treatment of a wide range of solid tumors and hematological malignancies. It acts by intercalating into DNA and inhibiting topoisomerase II, thereby blocking DNA replication and RNA synthesis, leading to irreversible cancer cell death.

Epirubicin is structurally related to doxorubicin but offers a more favorable therapeutic index with relatively lower cardiotoxicity, making it a preferred option in many breast cancer and combination chemotherapy protocols.

This injection is administered intravenously under strict oncology supervision and is extensively used in hospitals, cancer institutes, and specialty oncology centers.

Each vial contains:

• Epirubicin Hydrochloride BP – 10 mg / 25 mg / 50 mg / 100 mg

• Excipients: q.s. (sterile aqueous solution suitable for IV administration)

Epirubicin HCl for Injection BP is indicated for the treatment of:

• Breast Cancer

  • Adjuvant and neoadjuvant therapy

  • Locally advanced and metastatic breast cancer

• Ovarian Cancer

• Gastric (Stomach) Cancer

• Esophageal Cancer

• Lung Cancer (Non-Small Cell and Small Cell)

• Pancreatic Cancer

• Soft Tissue Sarcomas

• Hodgkin’s Lymphoma

• Non-Hodgkin’s Lymphoma

• Bladder Cancer (Intravesical administration as per protocol)

• Combination Chemotherapy Regimens for advanced and recurrent malignancies

• Palliative cancer treatment where tumor burden reduction is required

• Route: Intravenous injection or infusion only

• Dose: Typically 60–100 mg/m² every 21 days (varies by cancer type and protocol)

• Administration: Slow IV injection or diluted IV infusion

• Monitoring:

  • Cardiac function (ECG, LVEF)

  • Complete blood count (CBC)

  • Liver function tests

⚠ For use only by trained oncology professionals

• Available strengths: 10 mg, 25 mg, 50 mg, 100 mg

• Sterile single-use vial

• Hospital and bulk packaging available

• Store below 25°C

• Protect from light

• Do not freeze

• Keep out of reach of children

Cyclophosphamide for Injection BP

Cyclophosphamide for Injection BP is a broad-spectrum alkylating antineoplastic and immunosuppressive agent widely used in the treatment of various cancers and autoimmune disorders. It works by cross-linking DNA strands, thereby inhibiting DNA replication and cell division, leading to death of rapidly proliferating malignant cells.

This injection is an essential drug in oncology chemotherapy regimens, hematological malignancies, and immunosuppressive therapy, and is administered intravenously under strict medical supervision in hospital settings.

Each vial contains:

• Cyclophosphamide BP – 200 mg / 500 mg / 1 g

• Excipients: q.s. (sterile lyophilized powder for injection)

Cyclophosphamide for Injection BP is indicated for the treatment of:

• Breast Cancer

• Ovarian Cancer

• Lung Cancer (Small Cell and Non-Small Cell)

• Lymphomas (Hodgkin’s and Non-Hodgkin’s)

• Leukemias (Acute and chronic forms)

• Multiple Myeloma

• Neuroblastoma

• Sarcomas (Soft tissue and bone sarcomas)

• Germ Cell Tumors

• Solid tumors as part of combination chemotherapy protocols

• Severe Rheumatoid Arthritis

• Systemic Lupus Erythematosus (SLE)

• Nephrotic Syndrome

• Vasculitis (e.g., Wegener’s Granulomatosis)

• Organ Transplant Rejection Prevention

• Route: Intravenous (IV) injection or infusion

• Dose: Based on body surface area (mg/m²) or clinical protocol

• Administration: Reconstituted with sterile water for injection before IV use

• Monitoring:

  • CBC (hematological monitoring)

  • Renal and liver function

  • Adequate hydration recommended to reduce bladder toxicity

⚠ Administer only under supervision of an experienced oncologist

• Available strengths: 200 mg, 500 mg, 1 g vials

• Sterile lyophilized powder for injection

• Hospital and bulk packaging available

• Store below 25°C

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Ifosfamide for Injection BP

Ifosfamide for Injection BP is a powerful alkylating antineoplastic agent belonging to the oxazaphosphorine class, structurally related to cyclophosphamide. It is widely used in the treatment of advanced and refractory cancers, particularly sarcomas and solid tumors.

Ifosfamide acts by cross-linking DNA strands, leading to inhibition of DNA synthesis and cell division, ultimately causing cancer cell death. It is commonly administered as part of combination chemotherapy regimens and is often used alongside mesna to reduce urothelial toxicity.

This injection is intended for intravenous use only and must be administered under specialist oncology supervision.

Each vial contains:

• Ifosfamide BP – 500 mg / 1 g / 2 g

• Excipients: q.s. (sterile lyophilized powder for injection)

Ifosfamide for Injection BP is indicated in the treatment of:

• Soft Tissue Sarcomas

• Osteosarcoma

• Ewing’s Sarcoma

• Rhabdomyosarcoma

• Testicular Cancer (refractory or relapsed)

• Ovarian Cancer

• Cervical Cancer

• Lung Cancer (Small Cell & Non-Small Cell)

• Gastric Cancer

• Pancreatic Cancer

• Hodgkin’s Lymphoma

• Non-Hodgkin’s Lymphoma

• Pediatric malignancies as per oncology protocols

• Second-line or salvage chemotherapy for resistant cancers

• Combination chemotherapy regimens in advanced cancers

• Route: Intravenous injection or infusion

• Dose: Calculated based on body surface area (mg/m²) and treatment protocol

• Administration: Reconstituted with sterile diluent prior to IV use

• Special Requirement: Co-administration of Mesna recommended to prevent hemorrhagic cystitis

• Monitoring: CBC, renal function, neurological status, hydration status

⚠ For hospital use only under experienced oncology supervision

• Available strengths: 500 mg, 1 g, 2 g vials

• Sterile lyophilized powder for injection

• Institutional and bulk packaging available

• Store below 25°C

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Oxaliplatin for Injection BP

Oxaliplatin for Injection BP is a third-generation platinum-based antineoplastic (chemotherapy) agent widely used in the treatment of colorectal and other gastrointestinal cancers. It acts by forming DNA cross-links, which inhibit DNA replication and transcription, resulting in apoptosis of rapidly dividing cancer cells.

Oxaliplatin is most commonly used in combination chemotherapy regimens such as FOLFOX, offering improved survival outcomes in patients with advanced and metastatic cancers. It is intended for intravenous administration under specialist oncology supervision.

Each vial contains:

• Oxaliplatin BP – 50 mg / 100 mg

• Excipients: q.s. (sterile lyophilized powder for injection)

• Colorectal Cancer

  • Metastatic colorectal cancer

  • Adjuvant treatment of stage III colon cancer

• Gastric (Stomach) Cancer

• Esophageal Cancer

• Pancreatic Cancer

• Biliary Tract Cancer

• Ovarian Cancer (as part of combination therapy)

• Advanced or refractory solid tumors

• Combination chemotherapy regimens (e.g., FOLFOX, XELOX)

• Palliative chemotherapy in advanced malignancies

• Route: Intravenous infusion only

• Dose: Typically 85 mg/m² every 2 weeks or as per protocol

• Administration: Diluted in glucose solution and infused over 2–6 hours

• Monitoring: Neurological symptoms, hematological profile, renal function

⚠ For hospital use only under experienced oncologist supervision

• Available strengths: 50 mg and 100 mg vials

• Sterile lyophilized powder for injection

• Hospital and bulk packaging available

• Store below 25°C

• Protect from light

• Do not freeze

• Keep out of reach of children

Cisplatin for Injection BP

Cisplatin for Injection BP is a platinum-based antineoplastic (chemotherapy) agent widely used in the treatment of a broad range of solid tumors. It exerts its anticancer activity by forming DNA cross-links, which inhibit DNA replication and transcription, leading to cell death in rapidly dividing cancer cells.

Cisplatin is considered a cornerstone chemotherapy drug and is commonly used in first-line and combination chemotherapy regimens for many cancers. The injection is administered intravenously under strict oncology supervision in hospital settings.

Each vial contains:

• Cisplatin BP – 10 mg / 25 mg / 50 mg / 100 mg

• Excipients: q.s. (sterile solution or lyophilized powder for injection, depending on formulation)

Cisplatin for Injection BP is indicated for the treatment of:

• Testicular Cancer (first-line therapy, curative intent)

• Ovarian Cancer

• Bladder Cancer

• Lung Cancer (Small Cell and Non-Small Cell)

• Head and Neck Cancers

• Cervical Cancer

• Esophageal Cancer

• Gastric (Stomach) Cancer

• Pancreatic Cancer

• Breast Cancer (selected regimens)

• Combination chemotherapy protocols with other anticancer agents

• Radiation sensitizer in concurrent chemoradiotherapy

• Palliative treatment in advanced and metastatic malignancies

• Route: Intravenous infusion only

• Dose: Based on body surface area (mg/m²) and treatment protocol

• Administration: Diluted in suitable IV fluids and infused slowly

• Precautions: Adequate hydration and renal function monitoring required

• Monitoring: Kidney function, electrolytes, CBC, hearing function

⚠ For use only under experienced oncologist supervision

• Available strengths: 10 mg, 25 mg, 50 mg, 100 mg vials

• Sterile injection in vial

• Hospital and bulk packaging available

• Store below 25°C

• Protect from light

• Do not freeze

• Keep out of reach of children

Carboplatin for Injection BP

Carboplatin for Injection BP is a platinum-based antineoplastic (chemotherapy) agent widely used in the treatment of solid tumors and advanced cancers. It acts by forming DNA cross-links, inhibiting DNA replication and transcription, and ultimately inducing cancer cell apoptosis.

Carboplatin is a second-generation platinum compound, designed to reduce the nephrotoxicity and gastrointestinal side effects associated with cisplatin while maintaining strong anticancer efficacy. It is commonly used in combination chemotherapy regimens, especially for gynecological, lung, and head-and-neck cancers, and is administered intravenously under specialist oncology supervision.

Each vial contains:

• Carboplatin BP – 150 mg / 300 mg / 450 mg / 600 mg

• Excipients: q.s. for injection (sterile lyophilized powder or solution)

• Ovarian Cancer – first-line and recurrent treatment

• Non-Small Cell and Small Cell Lung Cancer

• Testicular Cancer – as part of combination chemotherapy

• Head and Neck Cancer

• Bladder Cancer

• Cervical Cancer

• Endometrial Cancer

• Gastrointestinal Cancers (stomach, esophagus)

• Combination chemotherapy protocols (e.g., Carboplatin + Paclitaxel, Carboplatin + Etoposide)

• Palliative treatment in advanced malignancies

• Alternative for patients intolerant to cisplatin

• Route: Intravenous infusion only

• Dose: Calculated using the Calvert formula (mg = target AUC × [GFR + 25]) or per treatment protocol

• Administration: Diluted in suitable IV fluids, infused slowly over 30–60 minutes

• Monitoring: Renal function, hematological parameters, and electrolytes

⚠ Administer only under experienced oncology supervision

• Available strengths: 150 mg, 300 mg, 450 mg, 600 mg vials

• Sterile lyophilized powder or solution for injection

• Institutional and hospital packaging available

• Store below 25°C

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Gemcitabine for Injection BP

Gemcitabine for Injection BP is a nucleoside analog antineoplastic agent widely used for the treatment of solid tumors and advanced malignancies. It acts by incorporating into DNA during replication, causing chain termination and inhibition of DNA synthesis, ultimately leading to apoptosis of rapidly dividing cancer cells.

Gemcitabine is commonly used as monotherapy or in combination chemotherapy regimens for cancers of the lung, pancreas, bladder, breast, and ovaries, as well as other solid tumors. It is intended for intravenous administration under specialist oncology supervision.

Each vial contains:

• Gemcitabine Hydrochloride BP – 200 mg / 1 g

• Excipients: q.s. for injection (sterile lyophilized powder or solution)

• Non-Small Cell Lung Cancer (NSCLC) – first-line and metastatic treatment

• Pancreatic Cancer – advanced and metastatic cases

• Bladder Cancer – locally advanced and metastatic

• Breast Cancer – metastatic or in combination therapy

• Ovarian Cancer

• Soft Tissue Sarcomas

• Head and Neck Cancers

• Esophageal Cancer

• Combination chemotherapy regimens (e.g., Gemcitabine + Cisplatin, Gemcitabine + Carboplatin)

• Palliative chemotherapy for advanced cancers

• Route: Intravenous infusion only

• Dose: Typically 1000–1250 mg/m² IV over 30 minutes once weekly for 3 weeks followed by 1-week rest, depending on protocol

• Monitoring: Hematological profile, liver function, renal function, and electrolytes

• Precautions: Administer under hospital or oncology supervision

• Available strengths: 200 mg and 1 g vials

• Sterile lyophilized powder or solution for injection

• Hospital and bulk packaging available

• Store below 25°C

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Docetaxel (Lyophilized) for Injection BP

Docetaxel for Injection BP is a semisynthetic taxane antineoplastic agent widely used in the treatment of solid tumors, including breast, lung, prostate, gastric, and head-and-neck cancers. It works by promoting the assembly of microtubules and inhibiting their depolymerization, thereby disrupting mitotic spindle formation and blocking cell division, leading to apoptosis of rapidly dividing cancer cells.

This lyophilized formulation ensures stability and extended shelf life, making it ideal for hospital and institutional use. Docetaxel is commonly administered as monotherapy or in combination chemotherapy regimens under specialist oncology supervision.

Each vial contains:

• Docetaxel BP – 20 mg / 40 mg / 80 mg / 100 mg

• Excipients: q.s. for lyophilized injection

After reconstitution with a suitable solvent, it is ready for intravenous infusion.

• Breast Cancer – adjuvant, neoadjuvant, metastatic therapy

• Non-Small Cell Lung Cancer (NSCLC) – advanced and metastatic

• Prostate Cancer – hormone-refractory metastatic cases

• Gastric (Stomach) Cancer

• Head and Neck Cancers

• Ovarian Cancer

• Esophageal Cancer

• Combination chemotherapy protocols (e.g., Docetaxel + Cisplatin, Docetaxel + Capecitabine)

• Second-line therapy for relapsed or refractory cancers

• Palliative chemotherapy in advanced malignancies

• Route: Intravenous infusion only

• Dose: Typically 75–100 mg/m² IV over 1 hour every 3 weeks, depending on protocol and cancer type

• Monitoring: Hematological profile, liver function, renal function, fluid retention, and neuropathy

• Precautions: Pre-medication with corticosteroids recommended to prevent hypersensitivity and fluid retention

⚠ Administer only under experienced oncology supervision

• Available strengths: 20 mg, 40 mg, 80 mg, 100 mg vials

• Lyophilized powder for injection

• Hospital and bulk packaging available

• Store below 25°C

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Paclitaxel (Lyophilized) for Injection BP

Paclitaxel for Injection BP is a semisynthetic taxane antineoplastic agent widely used in the treatment of solid tumors including breast, ovarian, lung, and head-and-neck cancers. It works by stabilizing microtubules and preventing their depolymerization, which disrupts mitotic spindle formation, halts cell division, and induces apoptosis of rapidly dividing cancer cells.

The lyophilized formulation ensures enhanced stability and shelf life, making it ideal for hospital, oncology center, and institutional use. Paclitaxel is commonly administered intravenously as monotherapy or in combination chemotherapy regimens under oncology supervision.

Each vial contains:

• Paclitaxel BP – 30 mg / 100 mg / 150 mg / 300 mg

• Excipients: q.s. for lyophilized injection

After reconstitution with suitable solvent, it is ready for intravenous infusion.

• Breast Cancer – adjuvant, neoadjuvant, and metastatic therapy

• Ovarian Cancer – advanced and recurrent cases

• Non-Small Cell Lung Cancer (NSCLC) – locally advanced or metastatic

• Head and Neck Cancers

• Esophageal Cancer

• Gastric (Stomach) Cancer

• Kaposi’s Sarcoma

• Pancreatic Cancer

• Combination chemotherapy protocols (e.g., Paclitaxel + Carboplatin, Paclitaxel + Cisplatin)

• Second-line therapy for relapsed or refractory cancers

• Palliative chemotherapy in advanced malignancies

• Route: Intravenous infusion only

• Dose: Typically 175 mg/m² IV over 3 hours every 3 weeks, depending on protocol and cancer type

• Monitoring: Hematological profile, liver function, neuropathy, hypersensitivity reactions

• Precautions: Pre-medication with corticosteroids, antihistamines, and H2 blockers recommended to prevent hypersensitivity

⚠ Administer only under experienced oncology supervision

• Available strengths: 30 mg, 100 mg, 150 mg, 300 mg vials

• Lyophilized powder for injection

• Hospital and bulk packaging available

• Store below 25°C

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Bleomycin for Injection BP

Bleomycin for Injection BP is an antineoplastic antibiotic derived from Streptomyces verticillus, used in chemotherapy for various malignancies. It works by binding to DNA and causing strand breaks, which inhibits DNA synthesis and induces apoptosis in rapidly dividing cancer cells.

This sterile injectable formulation is intended for intravenous, intramuscular, or subcutaneous administration under specialist supervision. Bleomycin is widely used in oncology hospitals, cancer centers, and specialty clinics for the management of solid tumors and certain hematological malignancies.

Each vial contains:

• Bleomycin Sulfate BP – 15 mg / 30 mg / 100 mg

• Excipients: q.s. sterile water for injection (lyophilized powder)

After reconstitution, it is ready for IV, IM, or SC administration.

• Hodgkin’s Lymphoma – as part of combination chemotherapy regimens (e.g., ABVD)

• Non-Hodgkin’s Lymphoma – selected treatment protocols

• Testicular Cancer – in combination with cisplatin and etoposide

• Squamous Cell Carcinoma – head, neck, and skin malignancies

• Gestational choriocarcinoma

• Combination chemotherapy for various solid tumors

• Adjunct therapy in multi-drug chemotherapy protocols

• Route: Intravenous (IV), Intramuscular (IM), or Subcutaneous (SC) injection

• Adult Dose: Typically 15 mg/m² IV/IM/SC per week, depending on regimen

• Pediatric Dose: Weight-based, adjusted per oncology protocol

• Monitoring: Pulmonary function, renal function, liver function, and hematologic parameters

⚠ Administer only under oncology specialist supervision

• Available strengths: 15 mg, 30 mg, 100 mg vials

• Lyophilized powder for injection

• Hospital and bulk packaging available

• Store 2–8°C (Refrigerated)

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Temozolomide Tablets BP – 250 mg

Temozolomide Tablets BP is an oral alkylating anticancer agent primarily used in the treatment of malignant brain tumors. It works by damaging tumor DNA, thereby inhibiting cancer cell replication and inducing apoptosis.

Temozolomide is widely used in neuro-oncology for both newly diagnosed and recurrent gliomas, often as part of combined chemoradiation therapy. Due to its oral administration and favorable CNS penetration, it is a preferred chemotherapy agent in brain cancer management.

Each tablet contains:

• Temozolomide BP – 250 mg

• Excipients: q.s.

• Glioblastoma multiforme (GBM)

  • Newly diagnosed GBM (concomitant with radiotherapy and as maintenance therapy)

  • Recurrent or progressive GBM

• Anaplastic astrocytoma

  • Refractory or relapsed cases after standard therapy

• High-grade gliomas

• Central nervous system (CNS) tumors

• Metastatic brain tumors (off-label, under specialist supervision)

• Route: Oral

• Administration: Taken on an empty stomach or as advised by an oncologist

• Dose: Determined based on body surface area (mg/m²), treatment phase, and clinical condition

• Treatment Cycle: Usually given in 5-day cycles every 28 days

⚠ Strictly to be used under oncologist supervision
⚠ Blood counts must be monitored regularly

• Blister / strip packing

• Bottle packing (as per requirement)

• Export and hospital bulk packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Capecitabine Tablets BP – 500 mg

Capecitabine Tablets BP is an oral antineoplastic (chemotherapy) agent belonging to the fluoropyrimidine class. It is a prodrug of 5-fluorouracil (5-FU) that is selectively activated in tumor tissues, resulting in targeted cytotoxic effects on cancer cells while minimizing systemic toxicity.

Capecitabine is widely used in the treatment of colorectal cancer, breast cancer, and gastric cancer, either as monotherapy or in combination with other anticancer agents. Oral administration allows convenient outpatient chemotherapy, improving patient compliance.

Each film-coated tablet contains:

• Capecitabine BP – 500 mg

• Excipients: q.s.

• Colorectal cancer

  • Adjuvant treatment after surgical resection

  • Metastatic colorectal cancer

• Breast cancer

  • Metastatic breast cancer resistant to anthracycline and taxane therapy

  • Combination therapy with docetaxel

• Advanced gastric cancer

• Gastro-esophageal cancers

• Pancreatic and biliary tract cancers (off-label, under specialist supervision)

• Route: Oral

• Administration: Taken within 30 minutes after meals, as advised by an oncologist

• Dose: Calculated based on body surface area (mg/m²)

• Treatment Cycle: Usually administered in 14-day treatment followed by 7-day rest cycles

⚠ To be used strictly under oncologist supervision
⚠ Regular monitoring of blood counts and liver function required

• Blister / strip packing

• Bottle packing available

• Hospital and export-grade bulk packaging

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Methotrexate Tablets BP – 10 mg

Methotrexate Tablets BP is an antimetabolite and immunosuppressant drug used in the treatment of certain cancers, autoimmune disorders, and inflammatory diseases. It works by inhibiting dihydrofolate reductase, leading to suppression of DNA synthesis, cell replication, and immune activity.

Oral methotrexate is widely prescribed in oncology, rheumatology, dermatology, and gastroenterology for both short-term and long-term therapy, under strict medical supervision.

Each tablet contains:

• Methotrexate BP – 10 mg

• Excipients: q.s.

• Acute lymphoblastic leukemia (ALL)

• Choriocarcinoma and gestational trophoblastic disease

• Breast cancer (as part of combination chemotherapy)

• Osteosarcoma (low-dose oral therapy)

• Rheumatoid arthritis (moderate to severe)

• Severe psoriasis and psoriatic arthritis

• Crohn’s disease and other inflammatory bowel diseases (IBD)

• Route: Oral

• Administration: As prescribed; usually once weekly for autoimmune disorders

• Dose: Depends on indication, body weight, and clinical response

⚠ Important: Methotrexate must NOT be taken daily for non-cancer indications
⚠ Regular monitoring of blood counts, liver and kidney function is mandatory

• Blister / strip packaging

• Bottle packaging available

• Hospital and export bulk packing options

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Cyclophosphamide Tablets BP – 50 mg

Cyclophosphamide Tablets BP is an oral alkylating anticancer and immunosuppressive agent used in the treatment of various malignancies and severe autoimmune disorders. It works by interfering with DNA replication and cell division, leading to destruction of rapidly dividing cancer and immune cells.

Oral cyclophosphamide is widely used in oncology and immunology, either as monotherapy or in combination with other chemotherapeutic agents, under strict medical supervision.

Each tablet contains:

• Cyclophosphamide BP – 50 mg

• Excipients: q.s.

• Breast cancer

• Ovarian cancer

• Lymphomas (Hodgkin’s and Non-Hodgkin’s lymphoma)

• Leukemias (acute and chronic types)

• Multiple myeloma

• Severe rheumatoid arthritis

• Systemic lupus erythematosus (SLE)

• Nephrotic syndrome

• Vasculitis and other autoimmune disorders

• Route: Oral

• Administration: As prescribed by an oncologist or specialist

• Dose: Depends on indication, body weight, blood counts, and treatment protocol

⚠ Use strictly under specialist supervision
⚠ Regular monitoring of blood counts and renal function is essential

• Blister / strip packaging

• Bottle packaging available

• Hospital and export-grade bulk packaging options

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Hydroxyurea Tablets BP – 500 mg

Hydroxyurea Tablets BP is an antineoplastic and antimetabolite agent widely used in hematological disorders and certain cancers. It works by inhibiting ribonucleotide reductase, leading to suppression of DNA synthesis and cell proliferation, particularly in rapidly dividing cells.

Hydroxyurea is extensively prescribed in hematology, oncology, and sickle cell disease management, both as long-term therapy and disease-modifying treatment, under specialist supervision.

Each tablet contains:

• Hydroxyurea BP – 500 mg

• Excipients: q.s.

• Sickle cell disease – to reduce frequency of painful crises and need for transfusions

• Polycythemia vera

• Essential thrombocythemia

• Chronic myeloid leukemia (CML)

• Acute myeloid leukemia (AML) (adjunct therapy)

• Head and neck cancers (in combination with radiotherapy)

• Route: Oral

• Administration: As prescribed by a specialist

• Dose: Based on body weight, blood counts, and clinical response

⚠ Strict medical supervision required
⚠ Regular monitoring of complete blood count (CBC) is mandatory

• Blister / strip packaging

• Bottle packaging available

• Hospital and export bulk packing options

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Anastrozole Tablets BP – 1 mg

Anastrozole Tablets BP is a non-steroidal aromatase inhibitor used in the treatment of hormone-dependent breast cancer in postmenopausal women. It works by inhibiting the aromatase enzyme, thereby reducing estrogen production, which helps slow or stop the growth of estrogen-sensitive tumors.

Anastrozole is widely prescribed as adjuvant therapy, first-line treatment, and extended therapy in early and advanced breast cancer, offering effective long-term disease control.

Each film-coated tablet contains:

• Anastrozole BP – 1 mg

• Excipients: q.s.

• Early breast cancer in postmenopausal women (adjuvant therapy)

• Advanced or metastatic breast cancer (hormone-receptor positive)

• First-line treatment of hormone-dependent breast cancer

• Extended adjuvant therapy following tamoxifen

• Prevention of recurrence in estrogen-positive breast cancer

• Route: Oral

• Typical Dose: 1 mg once daily

• Administration: Can be taken with or without food

⚠ For use in postmenopausal women only
⚠ To be used strictly under oncologist supervision

• Blister / strip packaging

• Bottle packaging available

• Hospital and export-grade bulk packaging options

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Letrozole Tablets BP – 2.5 mg

Letrozole Tablets BP is a non-steroidal aromatase inhibitor used in the treatment of hormone-dependent breast cancer in postmenopausal women. It works by blocking the aromatase enzyme, significantly reducing estrogen production, which helps slow or stop the growth of estrogen-sensitive tumors.

Letrozole is widely prescribed as first-line therapy, adjuvant treatment, and extended adjuvant therapy for early and advanced breast cancer, offering effective long-term disease control.

Each film-coated tablet contains:

• Letrozole BP – 2.5 mg

• Excipients: q.s.

• Early breast cancer in postmenopausal women (adjuvant therapy)

• Advanced or metastatic breast cancer (hormone-receptor positive)

• First-line treatment of hormone-dependent breast cancer

• Extended adjuvant therapy following tamoxifen treatment

• Prevention of recurrence in estrogen-positive breast cancer

• Route: Oral

• Typical Dose: 2.5 mg once daily

• Administration: Can be taken with or without food

⚠ For use in postmenopausal women only
⚠ To be used strictly under oncologist supervision

• Blister / strip packaging

• Bottle packaging available

• Hospital and export-grade bulk packaging options

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Exemestane Tablets BP – 25 mg

Exemestane Tablets BP is a steroidal aromatase inhibitor used in the treatment of hormone-dependent breast cancer in postmenopausal women. It works by irreversibly inhibiting the aromatase enzyme, leading to reduced estrogen levels, which slows or halts the growth of estrogen-sensitive tumors.

Exemestane is widely prescribed as adjuvant therapy, extended therapy following tamoxifen, and in advanced breast cancer, offering effective long-term disease control.

Each film-coated tablet contains:

• Exemestane BP – 25 mg

• Excipients: q.s.

• Early breast cancer in postmenopausal women (adjuvant therapy)

• Advanced or metastatic breast cancer (hormone-receptor positive)

• Extended adjuvant therapy following tamoxifen treatment

• Prevention of recurrence in estrogen-positive breast cancer

• Hormone-sensitive postmenopausal breast cancer

• Route: Oral

• Typical Dose: 25 mg once daily

• Administration: Can be taken with or without food

⚠ For use in postmenopausal women only
⚠ Use strictly under oncologist supervision

• Blister / strip packaging

• Bottle packaging available

• Hospital and export-grade bulk packaging options

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Tamoxifen Citrate Tablets BP – 20 mg

Tamoxifen Citrate Tablets BP is a selective estrogen receptor modulator (SERM) used in the treatment and prevention of hormone receptor-positive breast cancer. It works by blocking estrogen receptors in breast tissue, thereby preventing tumor growth driven by estrogen.

Tamoxifen is widely prescribed as adjuvant therapy, metastatic breast cancer treatment, and for breast cancer risk reduction in high-risk patients. It is a well-established, orally administered anti-cancer agent with proven efficacy in postmenopausal and premenopausal women.

Each tablet contains:

• Tamoxifen Citrate BP – 20 mg

• Excipients: q.s.

• Early breast cancer (adjuvant therapy)

• Advanced or metastatic breast cancer

• Breast cancer prevention in high-risk women

• Treatment of hormone receptor-positive tumors

• Management of ductal carcinoma in situ (DCIS)

• Reduction of breast cancer recurrence

• Route: Oral

• Typical Dose: 20 mg once or twice daily, depending on indication

• Administration: Can be taken with or without food

⚠ Strictly under oncologist supervision
⚠ Regular monitoring required for liver function and risk of thromboembolic events

• Blister / strip packaging

• Bottle packaging available

• Hospital and export-grade bulk packaging options

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Bicalutamide Tablets BP – 50 mg

Bicalutamide Tablets BP is a non-steroidal anti-androgen used in the treatment of prostate cancer. It works by blocking androgen receptors, thereby inhibiting the action of testosterone on prostate cancer cells, which slows tumor growth.

Bicalutamide is commonly prescribed in combination with luteinizing hormone-releasing hormone (LHRH) analogs for advanced prostate cancer or as monotherapy in certain cases, providing effective disease control with oral convenience.

Each tablet contains:

• Bicalutamide BP – 50 mg

• Excipients: q.s.

• Advanced prostate cancer (metastatic or locally advanced)

• Hormone-sensitive prostate cancer

• Adjunct therapy with LHRH analogs

• Prevention of tumor flare during LHRH agonist therapy

• Route: Oral

• Typical Dose: 50 mg once daily, as prescribed

• Administration: Can be taken with or without food

⚠ Use under strict oncologist supervision
⚠ Regular liver function monitoring recommended

• Blister / strip packaging

• Bottle packaging available

• Hospital and export-grade bulk packaging options

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Abiraterone Acetate Tablets BP – 250 mg

Abiraterone Acetate Tablets BP is an oral androgen biosynthesis inhibitor used in the treatment of advanced prostate cancer. It works by selectively inhibiting CYP17 enzyme, which blocks androgen production in the testes, adrenal glands, and tumor tissue, reducing tumor growth and progression in hormone-sensitive and castration-resistant prostate cancer.

Abiraterone is commonly prescribed in combination with prednisone for metastatic castration-resistant prostate cancer (mCRPC), offering effective disease control and improved patient outcomes.

Each tablet contains:

• Abiraterone Acetate BP – 250 mg

• Excipients: q.s.

• Metastatic castration-resistant prostate cancer (mCRPC)

• Advanced prostate cancer in combination with prednisone or corticosteroids

• Prevention of disease progression in hormone-sensitive advanced prostate cancer (off-label, specialist guidance)

• Adjunct therapy in prostate cancer management

• Route: Oral

• Typical Dose: 250 mg once daily (as per treatment protocol)

• Administration: Take on an empty stomach, at least 1 hour before or 2 hours after meals

• Combination: Administer with low-dose prednisone or as directed by oncologist

⚠ Use strictly under oncologist supervision
⚠ Monitor liver function and blood pressure regularly

• Blister / strip packaging

• Bottle packaging available

• Hospital and export-grade bulk packaging options

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Enzalutamide Tablets BP – 40 mg

Enzalutamide Tablets BP is a non-steroidal androgen receptor inhibitor used in the treatment of advanced prostate cancer. It works by blocking androgen receptors in prostate cancer cells, preventing testosterone from stimulating tumor growth and reducing disease progression in hormone-sensitive and castration-resistant prostate cancer.

Enzalutamide is commonly prescribed as monotherapy or in combination with androgen deprivation therapy (ADT) for metastatic castration-resistant prostate cancer (mCRPC), offering oral convenience and effective disease management.

Each tablet contains:

• Enzalutamide BP – 40 mg

• Excipients: q.s.

• Metastatic castration-resistant prostate cancer (mCRPC)

• Advanced prostate cancer in combination with androgen deprivation therapy (ADT)

• Prevention of disease progression in hormone-sensitive advanced prostate cancer (under specialist guidance)

• Adjunct therapy in prostate cancer management

• Route: Oral

• Typical Dose: 40 mg once daily (or as per oncologist’s protocol)

• Administration: Can be taken with or without food

⚠ Use strictly under oncologist supervision
⚠ Monitor liver function, blood pressure, and seizure risk regularly

• Blister / strip packaging

• Bottle packaging available

• Hospital and export-grade bulk packaging options

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Olaparib Tablets BP – 100 mg

Olaparib Tablets BP is an oral Poly (ADP-ribose) polymerase (PARP) inhibitor used in the targeted treatment of various advanced and metastatic cancers, particularly those associated with BRCA gene mutations.

Olaparib works by blocking PARP enzymes, preventing cancer cells from repairing damaged DNA, leading to selective cancer cell death while sparing normal cells. It is widely used in maintenance and monotherapy regimens for ovarian, breast, prostate, and pancreatic cancers.

Each film-coated tablet contains:

• Olaparib BP – 100 mg

• Excipients: q.s.

• Maintenance treatment of platinum-sensitive recurrent ovarian cancer

• Advanced ovarian cancer with BRCA1/BRCA2 mutation

• HER2-negative metastatic breast cancer with germline BRCA mutation

• Metastatic castration-resistant prostate cancer (mCRPC) with HRR gene mutation

• Metastatic pancreatic adenocarcinoma with germline BRCA mutation

• Maintenance therapy after response to platinum-based chemotherapy

• Targeted therapy in homologous recombination-deficient (HRD) tumors

• Route: Oral

• Usual Dose: As prescribed by oncologist (commonly twice daily dosing)

• Administration: Can be taken with or without food

⚠ Treatment should be initiated and monitored by a cancer specialist
⚠ Regular blood counts and renal function monitoring required

• Blister packs / HDPE bottles

• Hospital supply and bulk export packaging available

• Store below 30°C

• Protect from moisture and light

• Keep out of reach of children

Niraparib Tablets BP – 300 mg

Niraparib Tablets BP is an oral Poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of recurrent and advanced ovarian cancer and other homologous recombination deficiency (HRD)–positive malignancies.

Niraparib works by inhibiting PARP-1 and PARP-2 enzymes, leading to accumulation of DNA damage in cancer cells and ultimately tumor cell death, especially in tumors with BRCA mutations or DNA repair defects. It is widely used as first-line and maintenance therapy after platinum-based chemotherapy.

Each film-coated tablet contains:

• Niraparib BP – 300 mg

• Excipients: q.s.

• Maintenance treatment of recurrent epithelial ovarian cancer

• First-line maintenance therapy for advanced ovarian cancer

• Platinum-sensitive ovarian, fallopian tube, and primary peritoneal cancer

• BRCA-mutated ovarian cancer

• HRD-positive ovarian cancer regardless of BRCA status

• Maintenance therapy following response to platinum-based chemotherapy

• Targeted treatment in homologous recombination-deficient tumors

• Route: Oral

• Usual Dose: 300 mg once daily or as prescribed by an oncologist

• Administration: Can be taken with or without food

⚠ Dose adjustments may be required based on body weight and platelet count
⚠ Regular monitoring of blood counts and blood pressure recommended

• Blister packs / HDPE bottles

• Bulk and export-oriented packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children